Biotech

Biotech news roundup: Inside the discoveries, personalities, and deals driving drug development in general and biomedical engineering in particular. You’ll find coverage of biotech companies such as Eli Lilly, Biogen, Syndax, Intercept, and more.

Sign up for The Readout newsletter to get the latest on biotech delivered to your inbox, and subscribe to STAT+ to access daily, market-moving coverage of the biotech sector — from startup funding to clinical trial results.

Biotech Jonathan Saltzman — Boston Globe

STAT Plus: ‘Like playing the lottery’: A mixed picture for laid-off life sciences workers in Massachusetts

Some have bounced back with new jobs, while others have found competition very stiff for positions in the area's biotech industry, The Boston Globe reports.

Read The Story

Biotech Megan Molteni

All Coverage

Biotech Andrew Joseph

Biotech

STAT Plus: ‘Like playing the lottery’: A mixed picture for laid-off life sciences workers in Massachusetts

STAT Plus: In major test for eGenesis, gene-edited pig kidneys kept monkeys alive for more than two years

STAT Plus: Life sciences deals on track to hit lowest point since 2017

STAT Plus: Peter Marks on creating Operation Warp Speed, but for rare diseases

STAT Plus: Cell and gene therapies could be a safer bet than other drugs

All Coverage

STAT Plus: European regulators once again recommend Amylyx’s ALS drug be rejected

STAT Plus: European regulators consider appeal over Amylyx ALS drug

STAT Plus: With Ozempic, Wall Street moves on from a whole other class of medicines

STAT Plus: Sana to lay off nearly a third of staff, de-prioritize a key program

STAT Plus: Want a biotech buyout? Target cancer

STAT Plus: Akero’s treatment for NASH falls short in cirrhosis study

STAT Plus: Bristol ‘take-under’ of Mirati is not so great for biotech, but company’s new cancer target has potential

STAT Plus: FDA rejects Alnylam’s heart disease treatment over insufficient data

STAT Plus: Delfi launches its blood test to screen for lung cancer – and reveals challenges for liquid biopsies

STAT Plus: Inflammation gets its own research center, thanks to Chan Zuckerberg Initiative

STAT Plus: NIH funds expanded access projects for ALS

STAT Plus: FDA advisory panel signals lack of confidence in data on Amgen’s cancer drug

STAT Plus: Listen: Is the Nobel committee evolving? Plus, preventing public health’s wiliest virus

STAT Plus: Neurocrine reports second late-stage trial success for congenital adrenal hyperplasia drug

Moderna’s plan to make a single vaccine for Covid, influenza, and RSV is on track

STAT Plus: Kyowa Kirin to acquire Orchard Therapeutics, maker of gene therapy Libmeldy

STAT Plus: Scientists want to put carbon footprints on drugs. But it’s hard to get accurate numbers

STAT Plus: Failed biotech gives a rare peek inside the tough breaks — and tough choices — that led to its demise

STAT Plus: Consumer watchdog sues diagnostic firm EpicGenetics, alleging misleading claims about fibromyalgia test

STAT Plus: The major biotech news updates you need to read today

STAT Plus: FDA finds ‘potential systemic bias’ in Amgen’s KRAS drug trial ahead of advisory meeting

STAT Plus: When is a Wall Street disappointment ‘good enough’ for the FDA?

STAT Plus: Lilly bolts another one on, acquiring Point Biopharma for $1.4 billion

STAT Plus: Here’s what’s moving the needle in biotech stocks, in the final quarter of a dismal year

Biotech

Your daily dose of news in health and medicine Sign Up

All Coverage